Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

Core Insights - ALK announced the acceptance of real-world evidence regarding the clinical performance of the nasal adrenaline spray neffy for patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy, marking a significant milestone in its clinical evaluation [1][2]. Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma treatments, headquartered in Hørsholm, Denmark, employing around 2,800 people and listed on Nasdaq Copenhagen [6]. Product Information - Neffy is a ready-to-use, needle-free nasal adrenaline spray developed by ARS Pharmaceuticals, Inc., approved for emergency treatment of anaphylaxis. ALK holds exclusive global commercialization rights for neffy, except in the USA, Australia, New Zealand, Japan, and China [3][6]. - The product was launched in Germany in June 2025, with plans for additional launches in other EU markets by the end of the year [3]. Clinical Performance - The analysis indicated that 89.2% of 545 patients treated with a single dose of neffy were successfully managed, with 10.8% requiring a second dose. This effectiveness aligns closely with historical data for adrenaline injections, which report a success rate of 88.9% [2][4]. - The observational analysis was based on data from healthcare providers in the neffy experience program, which included 301 providers and 545 treated patients as of March 2025 [4].